💰 Financial Record

payment

← Back to List

Transaction Details

Amount

USD $2.5

Payer (From)

Pearl Therapeutics Linked to Pearl Therapeutics

Payee (To)

NLV-I Linked to NLV-I

Description

Investment exit multiple plus milestones

Additional Details

Date string: Past performance

Amount string: 2.5

Source document: HOUSE_OVERSIGHT_024043.jpg

📄 Source Document

HOUSE_OVERSIGHT_024043.jpg

ESTATE Collection

View Document

Document Summary

This document is page 32 of a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It outlines the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on biopharmaceutical companies with novel products or platforms. The text highlights past successes of the fund managers, listing exit multiples for companies such as Array BioPharma, Pearl Therapeutics, and Epizyme.

Discussion 0

No comments yet

Be the first to share your thoughts on this epstein financial record